Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Boston Scientific

Explore full profile

Boston Scientific, we work collaboratively to solve healthcare’s toughest problems by developing solutions that matter most to those suffering from debilitating

Marlborough, United StatesFounded 1979Health
Valuation $77B Market cap · 2026
Revenue $21B Latest reported FY
EBITDA $6.53B Latest reported FY

About Boston Scientific

Boston Scientific Corporation is a global leader in the development, manufacturing, and marketing of medical devices that are used in a broad range of interventional medical specialties. The company serves healthcare professionals and patients worldwide, focusing on areas such as cardiology, endoscopy, urology, and neuromodulation. Operating in the medical technology market, Boston Scientific's business model revolves around the continuous innovation of medical devices and solutions that address complex health conditions. Revenue is generated through the sale of these devices to hospitals, clinics, and other healthcare facilities. The company also invests heavily in research and development to maintain its competitive edge and expand its product portfolio.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1979
Headquarters
Marlborough, United States
Listing
IPO 1992
Employees
55,084
Open positions
430
Dealroom signal
84.9/100
Industry
Health
Sector
Health, Horizon Europe, DT and LS, observatoire healthtech
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
b2b, b2c
Investment activity
86 companies, latest May 2026
Capital deployed
$2.8B
Preferred round
ACQUISITION

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Feb 2026 $11B — Undisclosed ↗
POST IPO DEBT✓Debt Feb 2024 $2B — Undisclosed ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $21B +5.9% $6.5B 30.7% $3.8B 17.8% $2.1B
2025 $20B +19.9% $5.3B 26.6% $2.9B 14.4% $2.1B
2024 $17B +17.6% $4.3B 26% $1.9B 11.1% $1.6B
2023 $14B +12.3% $3.6B 25.4% $1.4B
2022 $13B +6.7% $2.8B 22.1%
2021 $12B +19.9% $2.8B 23.4%
2020 $9.9B — $1.8B 18.5%
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Boston Scientific website traffic

Latest recorded traffic for Boston Scientific is 620K monthly website visits. Boston Scientific's team grew 19.5% over the past year.

Latest monthly visits620K 1-year team growth+19.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

MirusMarietta, United StatesFocused on the design of innovative solutions for the treatment of spinal and orthopaedic degeneration and deformities $4.4Bvaluation PenumbraAlameda, United StatesPenumbra develops clinically beneficial products that help patients suffering from stroke and other neurovascular diseases $12Bvaluation Valencia TechnologiesSanta Clarita, United StatesAlencia Technologies is a neuromodulation company transforming the standard of care for bladder dysfunction $140Mvaluation Nalu MedicalCarlsbad, United StatesA range of medical devices $535Mvaluation SetPoint MedicalSanta Clarita, United StatesDeveloping novel bioelectronic medicine therapies to treat those who suffer from autoimmune diseases such as rheumatoid arthritis, Crohn's Disease and multiple sclerosis $460Mvaluation AnumanaCambridge, United StatesDeveloping and delivering ECG algorithms enabling early diagnosis and intervention $128Mvaluation SoniVieRosh Haayin, IsraelDeveloping a novel proprietary therapeutic intra-vascular ultrasound system (tivus) to treat a variety of hypertensive disorders, including pulmonary arterial hypertension (pah) $400Mvaluation 4C medicalMaple Grove, United StatesA medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR) $700Mvaluation Bolt MedicalCarlsbad, United StatesAdvanced intravascular lithotripsy platform addressing calcified cardiovascular disease challenges CortexSanta Clara, United StatesDeveloping an advanced, comprehensive platform for evaluating and treating AFib precisely, simply, and efficiently $289Mvaluation Intera OncologyWellesley, United StatesInnovative hepatic artery infusion pumps enhancing survival for colorectal and cholangiocarcinoma patients AblaconWheat Ridge, United StatesProvider of AI-guided atrial fibrillation therapies $120Mvaluation

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Railpen
  • Ardevora Asset Management

Other known investors1 additional known investor

  • Kleiner Perkins
Team profiled 991 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 12 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Marlborough HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Boston Scientific on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Boston Scientific’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.